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Abstract
Despite the emergence of numerous clinical and non-clinical applications of bright light therapy (LT) in recent
decades, the prevalence and severity of LT side effects have not yet been fully explicated. A few adverse LT effects
—headache, eye strain, irritability, and nausea—have been consistently reported among depressed individuals and
other psychiatric cohorts, but there exists little published evidence regarding LT side effects in non-clinical
populations, who often undergo LT treatment of considerably briefer duration. Accordingly, in the present study we
examined, in a randomized sample of healthy young adults, the acute side effects of exposure to a single 30-minute
session of bright white light (10,000 lux) versus dim red light (< 500 lux). Across a broad range of potential side
effects, repeated-measures analyses of variance revealed no significant group-by-time (Pre, Post) interactions. In
other words, bright light exposure was not associated with a significantly higher incidence of any reported side effect
than was the placebo control condition. Nevertheless, small but statistically significant increases in both eye strain
and blurred vision were observed among both the LT and control groups. Overall, these results suggest that the
relatively common occurrence of adverse side effects observed in the extant LT literature may not fully extend to non-
clinical populations, especially for healthy young adults undergoing LT for a brief duration.
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Introduction
Although medical curiosity about the salubrious benefits of
sunlight exposure can be traced to antiquity [1,2],
contemporary clinical interest was ignited by the 20th-century
discovery of a direct link between light exposure and circadian
melatonin production [3,4]. An obvious initial candidate for
bright light therapy (LT) was seasonal affective disorder [5] – a
form of depressive illness typically triggered by light deprivation
during the short, cold days of winter – and the intervention has
proven to be efficacious across a large number of randomized
controlled trials [6-8]. In fact, the efficacy of LT has now been
supported across a range of other mood disorders, including
non-seasonal depression [9,10,6], bipolar disorder [11,12],
antepartum and postpartum depression [13,14], and
premenstrual dysphoric disorder [15,16].
Light therapy (LT) has also been successfully applied to the
treatment of sleep disorders [17-20], as well as circadian phase
sleep disorders associated with jet lag [21,22] and shift work
[23,24]. More recently, LT has shown promise as an
intervention for obsessive-compulsive symptoms [25],
behavioral disturbances and functioning in dementia and
Alzheimer’s disease [26,27], primary and secondary features of
Parkinson’s disease [28], attention deficit hyperactivity disorder
[29], seasonal variations in eating disturbances associated with
bulimia nervosa [30,31], and some symptoms of chronic
anorexia [32].
The most prominently promoted putative mechanism
underlying LT’s therapeutic effect is the inhibition and shifting
of melatonin production in the brain’s pineal gland, which may
in turn induce a therapeutic alteration of dysregulated circadian
rhythms [4]. In other words, LT can trigger a phase-shifting of
the brain’s circadian clock, with the strongest therapeutic effect
occurring in individuals with seasonal onset depression [6]. But
retinal bright light exposure is also capable of altering
neurotransmitter function in a number of cerebral circuits. For
example, such exposure directly influences serotonin turnover
in the brain, with the lowest rate of turnover in the winter, and
more rapid turnover with exposure to increased luminosity [33].
Likewise, LT appears to enhance dopamenergic transmission
in some brain regions [34,35].
Despite the established therapeutic potential of LT in
seasonal depression and potential usefulness across a wide
array of application, considerably less is known about the side
effects and tolerability of LT. While a handful of landmark
studies (e.g., [36-39]) have concluded that headache and eye/
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vision difficulties are the most common side effects of LT
among mood-disordered patients, we can identify only one
published study that has reported on the adverse effects of LT
while employing a placebo control [40]. Interestingly, this study
observed no significant differences in side effects between the
LT and placebo groups, although it is worth noting that the
dosage of light was considerably lower than that most
commonly prescribed in contemporary practice. One additional
study [41] examined the side effects of a head-mounted visor
that delivered white light at illuminance levels of 60 lux, 600 lux,
or 3500 lux, respectively. We do not regard this as an adequate
test of LT effects, however, in as much as it utilized a non-
standard light delivery method (visor) with considerably less
empirical support.
Perhaps most importantly, to our knowledge there exist no
published studies regarding the acute side effects of LT among
non-psychiatric populations. On the contrary, most of what we
know about LT side effects comes from the study of mood-
disordered individuals, who are known to exhibit increased
attentional vigilance for negative information [42], along with an
increased propensity to interpret physiological changes as
aversive [43], and increased sensation of anticipatory pain [44].
Such depressive interpretive biases could conceivably lead to
the over-reporting of adverse effects while undergoing
interventions such as LT. Accordingly, the examination of LT
side effects among non-psychiatric individuals has the potential
to be of some conceptual and applied utility. Moreover, we are
aware of no placebo-controlled examinations of LT side effects
utilizing the most commonly prescribed dosage and duration of
LT -10,000 lux for 30 minutes [45].
The purpose of the present investigation, therefore, is to
address the aforementioned gaps in the extant LT literature.
Specifically, we evaluated the side effect profile of healthy
young adults undergoing a 30-minute session of standard LT in
comparison with that of a placebo control condition (of less
than 500 lux red light). Since most LT side effects are known to
emerge during the initial session and to diminish with repeated
exposures [38], the present study evaluated the side effects
associated with only one session at the currently prescribed
dose and illuminance (10,000 lux).
Materials and Methods
Ethics Statement
Participants provided written informed consent, and the study
was approved by the University of Kansas Institutional Review
Board.
Participants
All study participants were recruited from an introductory
psychology class at a large university in the midwestern United
States. Exclusion criteria included only a self-reported history
of bipolar disorder or retinal light sensitivity. However, nine
participants were also excluded from the final study analyses
because they reported a history of major depressive disorder.
An additional six participants endorsed every item on a side
effect questionnaire administered prior to the study’s light
exposure manipulation, as this presumably indicated either the
presence of clinically significant symptomatology or a
misunderstanding of study instructions and were excluded from
analyses.
Procedure
Artificial bright light was provided by a Sunlight Jr. light box
(The Sunbox Company, Gaithersburg, MD). The Sunlight Jr. is
a triangular box (14.5" Tall x 7" Wide (Face) x 6″ Sides) that
emits a full spectrum of light and employs a spectrally
transparent prismatic diffuser to block ultraviolet rays. At a
distance of 14 inches, the box emits an illuminance of 10,000
lux. A red filter was positioned over the prismatic diffuser to
filter all but red light and thereby to reduce the illuminance to
approximately 450 lux at a distance of 14 inches.
After the consent process, participants completed a brief
assessment battery to determine study eligibility, after which
eligible participants were randomly assigned, via a computer
generated random ordered list, either to the bright white light
condition (10,000 lux) or the low-level red light condition
(approximately 450 lux). In both light conditions, individuals
were seated alone at a table in a room with a light box
positioned 14 inches from their eyes, above their head, and
facing them at a 45 degree angle. To maintain a naturalistic
balance between the experimental light sources and the
ambient room light, the experiment room’s fluorescent
overhead lighting was dimmed to 50 lux.
During the 30-minute light exposure, participants were
instructed to read popular culture and/or current events
magazines provided by the experimenters, and to maintain
gaze forward, i.e., in the direction of the overhead light box. An
experimenter unobtrusively monitored adherence to the
procedural instructions throughout the session, but did not
interact with the participants in any other capacity. After the 30-
minute exposure, participants completed a final assessment
battery. All sessions occurred between 8:00 a.m. and 11:00
a.m. in a room with no natural light sources. Data collection
began in November 2010 and ended in mid-December 2011.
Measures
The Toronto Side Effect Scale (TSES) is a 32-item clinician-
rated instrument that measures the occurrence of adverse
treatment events [46]; it assesses both frequency (never –
everyday) and severity (no trouble – extreme trouble) on a 5-
point Likert-type scale. The TSES is well-suited to modification
in line with specific treatment study goals (e.g. [47,48]).
Accordingly, TSES was modified in the present investigation by
excluding 15 items that measure side effects of psychotropic
medication inapplicable to LT (e.g. sexual dysfunction, weight
loss/gain), along with the addition of two items to reflect
symptoms specifically relevant to LT (e.g. irritability, eye strain).
The aforementioned modifications yielded a 19-item self-report
measure of physiological symptoms of potential relevance to
LT. Additionally, the TSES frequency scale was slightly
modified to present a binary choice regarding the presence or
absence of each side effect, while the measure’s 5-point side
effect severity scale was preserved but relabeled to facilitate
greater participant comprehension (mild – severe). Finally, a
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total side effect intensity score was calculated as the sum total
of severity ratings across the measure’s 19 items.
Data Analysis
All data analyses were conducted using PASW Statistics 18,
Release Version 18.0.0 (SPSS, Inc., 2009, Chicago, IL,
www.spss.com). First, the presence of potentially confounding
between-group differences on demographic variables (gender,
age), recent outdoor light exposure, and relevant clinical
characteristics (sleep quantity and physiological symptoms
present prior to LT) were tested by means of univariate
analyses of variance. A within-subjects, repeated measures,
2x2 factorial design using time (pre, post) by condition (bright
light, red light) was used to analyze potential side effects.
Specifically, main effects of time (pre, post) and light condition
(bright white, dim red), as well as a time-by-condition
interaction effect, were analyzed using a repeated measures
analysis of variance (ANOVA) for total side effect intensity and
severity of the most commonly reported side effects of LT as
measured by the TSES. Effect sizes were calculated using
Cohen’s d [49]. To limit the potential inflation of experimentwise
Type I error due to multiple significance tests, an alpha level
of .01 was utilized in all analyses.
A post hoc analysis was also conducted to examine
seasonal variability in report of side effects. A within-subjects,
repeated measures, 2x2x4 factorial design – time (pre, post) by
condition (bright light, red light) by season (summer, fall, winter,
spring) – was used to analyze changes in each side effect.
Similarly, an alpha level of .01 was utilized to limit inflation of
Type I error.
Results
Two hundred and thirteen undergraduate students (56.3%
female) met criteria for the study and were included in the final
analyses. The age of participants ranged from 18 to 32 (M =
19, SD = 2) who slept an average of 6.8 hours (SD = 1.5) the
night before the study. One hundred and twelve (52.6%)
participants were randomized into the red light control group,
and 101 into the bright light group. The percentage of
participants in each group did not differ significantly by gender,
X2 (1, N = 213) = .06, p = .80. Likewise, univariate analyses of
variance revealed no significant preexisting differences in
baseline characteristics between participants in the two
experimental conditions on age (t[211] = -.93, p = .35), hours of
sleep (t[211] = .31, p = .76), or time spent outdoors prior to the
experiment (t[209] = .01, p = .99). Similarly, no pre-treatment
differences were seen for nausea (t[21] = .18, p = .86),
headache (t[211] = -.03, p = .98), blurred vision (t[211] = 1.28,
p = .20) or eye strain (t[211] = .16, p = .87). Table 1 presents
the severity of side effects at pre-treatment and post-treatment
for each light condition.
Analysis of variance (ANOVA) showed a significant main
effect of time on eye strain, F(1, 211) = 32.36, p < .001, d = .47,
and blurred vision, F(1, 211) = 7.60, p = .006, d = .19. Across
both groups, the average post-treatment eye strain severity (M
= .4, SD = 1.0) was greater than pre-treatment severity (M = .1,
SD = .5); likewise, average post-treatment blurred vision
severity (M = .2, SD = .5) was greater than the pre-treatment
mean (M = .1, SD = .4). A significant main effect of time was
also observed for nervousness, F(1, 209) = 40.01, p < .001, muscle twitching, 
Table 1. Average Side Effect Intensity for Dim Red and
Bright White Light at Pre-Treatment and Post-Treatment.
 Pre-Treatment Post-Treatment
 Red White Red White
Symptom Mean SD Mean SD Mean SD Mean SD
Nervousness .5 (.8) .6 (1.1) .1 (.5) .3 (.8)
Agitation .1 (.3) .3 (.7) .2 (.7) .2 (.6)
Tremor or shakiness .1 (.5) .1 (.5) .1 (.5) .1 (.3)
Muscle twitching .2 (.6) .1 (.4) .1 (.2) .1 (.3)
Abdominal pain .2 (.6) .1 (.4) .1 (.4) .1 (.3)
Upset stomach .2 (.7) .3 (.7) .1 (.5) .2 (.6)
Nausea .1 (.4) .1 (.4) .1 (.4)  0 (.2)
Weakness or fatigue .5 (1.0) .7 (1.2) .7 (1.2) .7 (1.3)
General dizziness .1 (.4) .1 (.4) .2 (.5) .2 (.6)
Daytime drowsiness .6 (1.1)  1.0 (1.4) .8 (1.2) .9 (1.3)
Sweating .1 (.5) .3 (.8)  0 (.1)  0 (.2)
Flushing  0 (.3) .1 (.4)  0 (.1)  0 (.3)
Headache .4 (1.0) .4 (.9) .5 (.9) .5 (1.0)
Blurred vision .1 (.5) .1 (.3) .2 (.5) .2 (.5)
Eye strain .1 (.5) .1 (.4) .5 (1.0) .4 (.9)
Dry mouth .1 (.5) .3 (.7) .2 (.6) .2 (.6)
Irritability .2 (.6) .2 (.6) .2 (.7) .1 (.5)
Restless energy .2 (.6) .2 (.6) .2 (.7) .2 (.7)
Total side effect intensity  3.7 (5.3)  4.7 (6.1)  4.2 (5.6)  4.4 (5.3)
doi: 10.1371/journal.pone.0075893.t001
Acute Side Effects of Bright Light Therapy
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e75893
a single exposure, comparison to a dim light control, and a
sample of healthy young adults. However, the current results
are highly consistent with the only other placebo-controlled
study of adverse LT effects [41] in the extant literature. As in
the present investigation, Volz and colleagues observed no
significant differences in the side effects engendered by bright
light versus dim red light. However, because these
investigators utilized an outmoded light intensity by current
practices in their LT condition -2500 lux, as opposed to the
standard of 10,000 lux – the present study represents an
important replication and extension of their work. Likewise, it
stands as the first reported examination of LT side effects in a
non-clinical sample.
It is important to note, however, that we did observe modest
but statistically significant increases in the occurrence of two
side effects – eye strain and blurred vision – following light
exposure in the present study. But these small-magnitude
increases were equally likely among participants in both
treatment conditions, and were thus not specific effects of LT.
Specifically, at post-treatment, we observed eye strain
incidence rates of 22% and 23%, respectively, in the bright light
versus dim light exposure groups; likewise, we found incidence
rates of 12% versus 13%, respectively, for blurred vision
(Figure 1). The great majority of affected participants in both
groups rated these symptoms as only “mild” in severity. While
uncontrolled LT investigations have also reported such visual
side effects with bright light exposure [50], the present study
suggests that they are a consequence of neither the
illuminance nor the color of light. In fact, they may simply reflect
Table 2. Percentage of Side Effects Reported for Dim Red
and Bright White Light at Pre-Treatment and Post-
Treatment.
 Pre-Treatment Post-Treatment
 Red White Red White
Symptom (n = 112) (n = 101) (n = 112) (n = 101)
Nervousness 36 34 12 17
Agitation  6 14 13 11
Tremor or shakiness 10  7  6  7
Muscle twitching 12  8  6  5
Abdominal pain 12  4  8  4
Upset stomach 12 14  11 11
Nausea  5  5  7  2
Weakness or fatigue 29 32 39 31
General dizziness  6  5 13  9
Daytime drowsiness 33 42 45 44
Sweating 10 14  2  4
Flushing  2  5  1  1
Headache 18 22 32 27
Blurred vision  8  4 13 13
Eye strain  6  5 26 22
Dry mouth  9 15 13 14
Irritability 11 10 13 10
Restless energy 12 11 14 14
doi: 10.1371/journal.pone.0075893.t002
an artifact of the experimental task (reading) used to occupy
attention during the 30-minute light exposure procedure.
Perhaps the most surprising study finding was the
observation in both treatment groups of significant decreases in
three reported side effects – nervousness, muscle twitching,
and sweating – from pre-treatment to post-treatment. Rather
than posit some sort of beneficial placebo-like impact of acute
treatment on these three domains, we believe the finding is
best attributed to mere participant habituation of the
experimental setting.
The present study is characterized by a few important
limitations. Notably, the generalizability of the present findings
may be limited by the fact that we utilized only a single session
of light exposure – a procedure that contrasts sharply with the
typical administration of LT, which spans over a minimum of
several days, and often over several weeks. While previous
findings suggest that LT side effects tend to diminish over the
course of repeated exposure sessions [38], we cannot rule out
the possibility that some potential side effects were
insufficiently triggered by a single session’s exposure. In fact,
clarifying the pattern of temporal onset across potential LT side
effect domains is a task that warrants the attention of future
investigators in the area.
Another potential limitation lies in our use of a relatively
young participant sample – a mean age of 19 – with a low
average level of undesired physical symptoms at baseline (as
reflected in pre-treatment responses to the study’s side effects
measure). It would be desirable, therefore, to include in any
attempted replication participants with a broader range of ages,
including older individuals who may express greater variability
in adverse side effects. Furthermore, our sample was exposed
to bright light no earlier than 8 am, which contrasts with prior
studies that initiate exposure earlier in the morning. However,
college students are often phase shifted as indicated by our
sample’s average length of sleep (less than 7 hours). Thus, we
believe that the current investigation’s timing of exposure was
fairly congruent for the recommended timing when adjusting for
age.
Conclusion
The principal strength of the present study lies in its use of a
placebo control group, as well as a rather large sample size, in
a novel examination of LT-related side effects. The current
investigation also controls for the presence of any side effects
present prior to light exposure, thereby permitting an
examination of the directionality of side effect severity.
Commonly, studies of side effects only examine prevalence
rates after intervention – i.e., only the emergence or remission
of symptoms rather than their increase or decrease in severity.
Furthermore, the present study utilized the currently accepted
dosage of LT (10,000 lux) in a non-clinical sample, thereby
addressing a significant gap in the extant LT literature.
The present findings thus make a potentially significant
contribution to our understanding of LT side effects, an
important area of investigation in light of the increasingly
frequent use of LT in both clinical and non-clinical settings.
Specifically, our results indicate that the reported prevalence of
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acute adverse side effects in the published clinical literature
may not apply fully to non-clinical populations, as no increases
in headache or nausea emerged in the present investigation, in
contrast with the consensus of previously published reports.
Moreover, although eye strain and blurred vision increased
significantly (albeit modestly) from pre-treatment to post-
treatment, such increases occurred to an equivalent extent in
both the bright light and control conditions; thus, they did not
appear to be a function of bright light exposure, per se. Taken
together, the present study results suggest that LT may be
particularly well tolerated by non-clinical populations.
Nevertheless, further research is needed to clarify the extent to
which these results may extend beyond young, non-clinical
samples, as well as the degree to which some side effects may
emerge over the course of repeated LT exposure.
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